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Background
Immunity elicited by live attenuated vaccines confers pro-
tection against viral pathogens causing measles, yellow
fever, smallpox and others, but this approach is not well
suited to HIV vaccine development. Accordingly, to
develop a vaccine that incorporates features of a live virus
that make it immunogenic without the inherent safety
issues associated with attenuated lentiviruses, we are
developing replication-competent, recombinant vesicular
stomatitis virus (rVSV) vectors for delivery of SIV and
HIV vaccines.
Methods
An rVSV vector was constructed in which the natural
glycoprotein (G) was replaced with SIVmac239 Env, and
an additional transcription unit was introduced to encode
SIVmac239 Gag. The chimeric VSV deltaG-SIV virus
vaccine was rescued and evaluated in vitro and in vivo.
Results
Infection of susceptible cells with this chimeric rVSV-SIV
GagEnv virus produced infectious VSV particles contain-
ing functional SIV Env, and lentivirus-like particles con-
taining Gag and Env. Serial passage of rVSV-SIV GagEnv
vector in CD4+/CCR5+ cells resulted in improved replica-
tive fitness evident by a 2-log increase in infectious virus
titers. This adapted virus retained CD4/CCR5 dependence,
infected primary rhesus PBMCs and cells isolated from
lymph node and duodenum tissues ex vivo. Primary
human monocyte-derived dendritic cells (MDDCs) also
were susceptible to infection with the rVSV-SIV GagEnv
vector. Indian rhesus macaques were immunized with
increasing doses of rVSV-SIV GagEnv intramuscularly
(IM) to observe reactions to vaccination with this new
vector and to quantify immune responses. At the highest
dose of 1x108 PFU, no adverse reactions were observed
and serum antibody responses against Gag and Env were
elicited, which were boosted by IM immunization with
Ad5-SIV Gag and Ad5-SIV Env vectors.
Conclusion
A prototype chimeric VSV-SIV live virus vaccine was
developed and evaluated in the NHP model. Chimeric
VSV-SIV and VSV-HIV vaccine candidates designed for
improved replication and immunogenicity currently are
being evaluated in vitro and in vivo.
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